![PDF] Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d4b56019bf1c5c867f8dd86ecce095a3a9e8eeb2/3-Figure2-1.png "PDF] Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. | Semantic Scholar")
PDF] Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. | Semantic Scholar
Downregulation of MET in H1993 cells, effects of crizotinib on EGFR... | Download Scientific Diagram
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells | Oncogenesis
Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing - Lung Cancer
Crizotinib displays potent anti-tumour efficacy in an MET amplification... | Download Scientific Diagram
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification Justin. - ppt download
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib — ALK POSITIVE
Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition - Journal of Thoracic
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations - Journal of Thoracic Oncology
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib - Clinical Lung Cancer
Effect of Crizotinib on c-MET expression in c-MET altered cancer cells.... | Download Scientific Diagram
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study | Trials | Full Text
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - ScienceDirect
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation - Clinical Lung Cancer
Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
